Inpharma 1262 - 4 Nov 2000

■ Antithrombin III improves clinical and perinataloutcomes in pregnant women with pre-eclampsia,report investigators from Japan. In this study, 133women with pre-eclampsia who were at 24–35 weeks’gestation were randomised to receive IV antithrombinIII [‘Kybernin HS’] 3000U (n = 66) or human albumin582mg, once daily for 7 days.* Improvements frombaseline in Gestosis Index (GI) scores, fetal weightgain and biophysical profile scores were greater inantithrombin III, compared with human albumin,recipients; the between-group differences weresignificant for GI scores and fetal weight gain. Inaddition, gestation was significantly prolonged and thenumber of infants with low birthweight or who weresmall for gestational age was significantly smaller inantithrombin III, compared with human albumin,recipients.* The study was supported by Aventis Pharma Ltd., Tokyo, Japan,WelFide Corporation, Osaka, Japan and Aventis Behring GmbH,Marburg, Hessen, Germany.

Maki M, et al. Antithrombin therapy for severe preeclampsia: results of adouble-blind, randomized, placebo-controlled trial. Thrombosis andHaemostasis 84: 583-590, Oct 2000 800848629

1

Inpharma 4 Nov 2000 No. 12621173-8324/10/1262-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved